HK1224375A1 - 在評價心力衰竭中的用途 - Google Patents

在評價心力衰竭中的用途

Info

Publication number
HK1224375A1
HK1224375A1 HK16112526.0A HK16112526A HK1224375A1 HK 1224375 A1 HK1224375 A1 HK 1224375A1 HK 16112526 A HK16112526 A HK 16112526A HK 1224375 A1 HK1224375 A1 HK 1224375A1
Authority
HK
Hong Kong
Prior art keywords
mimecan
assessment
heart failure
heart
failure
Prior art date
Application number
HK16112526.0A
Other languages
English (en)
Inventor
Block Dirk
Arab Sara
Hess Georg
Huedig Hendrik
Liu Peter
Wienhues-Thelen Ursula-Henrike
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1224375A1 publication Critical patent/HK1224375A1/zh

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806Determination of free amino acids
    • G01N33/6812Assays for specific amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/325Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK16112526.0A 2009-07-27 2016-11-01 在評價心力衰竭中的用途 HK1224375A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09009666 2009-07-27

Publications (1)

Publication Number Publication Date
HK1224375A1 true HK1224375A1 (zh) 2017-08-18

Family

ID=41320068

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16112526.0A HK1224375A1 (zh) 2009-07-27 2016-11-01 在評價心力衰竭中的用途

Country Status (8)

Country Link
US (1) US10234462B2 (zh)
EP (1) EP2460015B1 (zh)
JP (1) JP5592487B2 (zh)
CN (2) CN105548563B (zh)
CA (1) CA2769243C (zh)
ES (1) ES2512018T3 (zh)
HK (1) HK1224375A1 (zh)
WO (1) WO2011012268A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2115477B1 (en) * 2007-01-25 2015-06-24 Roche Diagnostics GmbH Use of igfbp-7 in the assessment of heart failure
ES2595028T3 (es) 2011-10-17 2016-12-27 F. Hoffmann-La Roche Ag Diagnóstico basado en Troponina y BNP de pacientes en riesgo y causa de ictus
WO2014040759A1 (en) 2012-09-12 2014-03-20 Roche Diagnostics Gmbh Identification of patients with abnormal fractional shortening
JP6342914B2 (ja) * 2012-12-04 2018-06-13 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 心不全の治療選択におけるバイオマーカー
EP3470848A3 (en) 2014-01-28 2019-05-22 Roche Diagnostics GmbH Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides
EP3413052B1 (en) 2014-03-26 2022-12-28 Roche Diagnostics GmbH Igfbp7 for diagnosing diastolic dysfunction
US11011274B2 (en) * 2016-03-09 2021-05-18 Conduent Business Services, Llc Method and apparatus for predicting mortality of a patient using trained classifiers
CN110018309B (zh) * 2018-01-08 2023-07-04 成都市第三人民医院 通过蛋白标志物判断结直肠癌预后的试剂盒
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922873A1 (de) 1989-04-25 1990-10-31 Boehringer Mannheim Gmbh Spezifische antikoerper gegen troponin t, ihre herstellung und verwendung in einem reagenz zur bestimmung von hermuskelnekrosen
US6333397B1 (en) 1989-04-25 2001-12-25 Roche Diagnostics Gmbh Monoclonal antibodies to troponin T and their production
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
ATE281648T1 (de) 1995-04-18 2004-11-15 Biosite Diagnostics Inc Verfahren zum assay von troponin i und t und komplexen von troponin i und t und auswahl von antikörpern zur verwendung in immunoassays
DE50015291D1 (de) 1999-01-29 2008-09-11 Roche Diagnostics Gmbh Verfahren zum Nachweis von N-terminalem proBNP
AU7603800A (en) * 1999-09-24 2001-04-24 Human Genome Sciences, Inc. 32 human secreted proteins
AUPR005600A0 (en) * 2000-09-12 2000-10-05 University Of Sydney, The Diagnostic assay
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US6461828B1 (en) * 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure
CN1784425A (zh) 2003-05-12 2006-06-07 霍夫曼-拉罗奇有限公司 用结合天然脑钠尿肽前体分子氨基酸38-44的单克隆抗体检测天然脑钠尿肽前体分子的方法
US7358224B2 (en) 2003-05-29 2008-04-15 The University Of Manchester Class III SLRP agonists for the reduction of blood vessel formation
WO2006026557A2 (en) 2004-08-30 2006-03-09 Cervimark, Llc Methods and kits for predicting risk for peterm labor
US20080090759A1 (en) * 2004-08-30 2008-04-17 Robert Kokenyesi Methods and kits for predicting risk for preterm labor
GB0423273D0 (en) 2004-10-20 2004-11-24 Univ Manchester Treatment of cancer
US20060246484A1 (en) 2005-03-10 2006-11-02 Hare Joshua M Identification of gene expression by heart failure etiology
EP1929295A4 (en) * 2005-08-30 2010-03-17 Biosite Inc USE OF SOLUBLE FLT-1 AND ITS FRAGMENTS IN CARDIOVASCULAR CONDITIONS
CN1951967A (zh) * 2005-10-21 2007-04-25 上海第二医科大学附属瑞金医院 抗人骨生成诱导因子单克隆抗体及其制备和用途
ES2344993T3 (es) * 2006-03-24 2010-09-13 F. Hoffmann-La Roche Ag Medios y metodos para la diferenciacion de la necrosis de miocardio aguda y cronica en pacientes sintomaticos.
EP2115477B1 (en) * 2007-01-25 2015-06-24 Roche Diagnostics GmbH Use of igfbp-7 in the assessment of heart failure
DE102007010834A1 (de) 2007-03-03 2008-09-04 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Herzinsuffizienz für NYHA I Patienten
ES2339284T3 (es) * 2007-03-06 2010-05-18 F. Hoffmann-La Roche Ag Utilizacion de nogo-c en la deteccion de la insufuciencia cardiaca.
ATE537454T1 (de) 2007-05-24 2011-12-15 Hoffmann La Roche Verfahren zum beurteilen von herzinsuffizienz bei patienten mit vorhofflimmern mittels gdf-15
JP2011501113A (ja) * 2007-10-10 2011-01-06 エフ.ホフマン−ラ ロシュ アーゲー 急性冠症候群を有する患者での既存の心筋機能不全の評価のためのナトリウム利尿ペプチド/トロポニン比
WO2009061382A2 (en) * 2007-11-02 2009-05-14 Marban Eduardo T Cardiac stem cell and myocyte secreted paracrine factors and uses thereof

Also Published As

Publication number Publication date
US20120156703A1 (en) 2012-06-21
CN105548563A (zh) 2016-05-04
EP2460015B1 (en) 2014-08-20
JP2013500482A (ja) 2013-01-07
ES2512018T3 (es) 2014-10-23
WO2011012268A8 (en) 2011-06-30
CN102549436A (zh) 2012-07-04
CA2769243A1 (en) 2011-02-03
CN105548563B (zh) 2017-09-22
EP2460015A1 (en) 2012-06-06
CA2769243C (en) 2017-08-22
JP5592487B2 (ja) 2014-09-17
US10234462B2 (en) 2019-03-19
WO2011012268A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
HK1224375A1 (zh) 在評價心力衰竭中的用途
PL2115477T3 (pl) Zastosowanie IGFBP-7 do oceny niewydolności serca
ZA201007523B (en) Heart age assessment
GB0906642D0 (en) Cardiac pump
IL191773A0 (en) Cardiac mechanical assessment using ultrasound
HK1164766A1 (zh) 種植物大麻素或其組合用於治療癲癇症之用途
EP2487737A4 (en) BATTERY CONNECTING BODY
EP2327448A4 (en) defibrillation catheter
EP2346401A4 (en) DETECTOR FOR HEART FAILURE
EP2422837A4 (en) MEDICAL CONNECTOR STRUCTURE
EP2571422A4 (en) NON-INVASIVE DETERMINATION OF CARDIAC FLOW
EP2639173A4 (en) FRACTAL-LIKE ARTICULABLE STRUCTURE
IL207236A (en) Chair helps
HK1213324A1 (zh) 心力衰竭療法的選擇中的生物標記物
EP2512452A4 (en) ANTITHROMBOTIC NANOPARTICLE
EP2596828A4 (en) INTRAVASCULAR HEMOSTASIS TYPE CATHETER
EP2639884A4 (en) CONTACT AND CONTACT CONNECTION STRUCTURE
GB0908425D0 (en) Medical use
GB201012941D0 (en) Determining the extent of a structure on or in the skin of a subject
GB0916997D0 (en) Combination therapy
HK1173995A1 (zh) 二茂鐵喹在治療瘧疾中的用途
GB0907973D0 (en) Combination therapy
EP2496143A4 (en) HEART RATE MONITOR
TWM371982U (en) The connector
TWM401367U (en) Mattress structure having the sound-shock effect